This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jazz Pharmaceuticals Begins Clinical Trial Of Intravenously Administered Erwinaze® In Patients With Acute Lymphoblastic Leukemia

DUBLIN, Dec. 3, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze ® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

"Intravenous administration of Erwinaze may provide meaningful benefit to patients, their caregivers and families by avoiding the need for multiple intramuscular injections," stated Lynda Vrooman, MD, MSc, a pediatric oncologist at Dana-Farber/Children's Hospital Cancer Center and principal investigator of the trial.  "Intramuscular injections can be painful and difficult for patients, and this alternative route of administration, if it is shown to be feasible, would be an important advancement in the care of certain ALL patients, many of whom are young children."

The trial is designed to enroll up to 25 ALL patients in the U.S. and Canada who have a documented Grade 2 or higher hypersensitivity reaction to native or pegylated E. coli asparaginase and have not completed their full courses of prescribed asparaginase therapy.  Preliminary pharmacokinetic data from the trial are expected in the second half of 2013.

"This important clinical trial underscores our commitment to those patients with ALL who require treatment with Erwinaze," noted Jeffrey Tobias, MD, executive vice president of research and development, and chief medical officer of Jazz Pharmaceuticals.  "It also reflects our strategy of supporting our core growth products by investment in patient-centric initiatives."

About Acute Lymphoblastic Leukemia (ALL) Acute lymphoblastic leukemia affects approximately 6,000 Americans, 60 percent of whom are children.  ALL is the most common form of childhood cancer, with the peak incidence between two and five years of age.  ALL has a 90 percent survival rate with treatment including asparaginase-based regimens, but progresses quickly if left untreated.  A majority of asparaginase treatments derive from E. coli; however, approximately 15 to 20 percent of ALL patients develop hypersensitivity to E. coli-derived asparaginase regimens.  Erwinaze asparaginase-based therapy plays a critical role for patients with no other treatment options.

About Jazz Pharmaceuticals Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs.  The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.  The company's U.S. marketed products in these areas include: Xyrem ® (sodium oxybate) oral solution, Erwinaze ® (asparaginase  Erwinia chrysanthemi), Prialt ® (ziconotide) intrathecal infusion, Luvox CR ® (fluvoxamine maleate), FazaClo ® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements, including, but not limited to, statements related to enrollment and data collection in the Erwinaze IV administration trial and the timing thereof, the potential for future patient benefit from IV administration of Erwinaze, future product growth and investment and other statements that are not historical facts.  These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval, including the risks that the results from the clinical trial may be negative or inconclusive, which could preclude FDA approval of IV administration of Erwinaze and could result in adverse regulatory action related to the company's current Erwinaze commercial product, other risks related Jazz Pharmaceuticals' business, including dependence on sales of Xyrem ® and the company's ability to maintain and increase sales of Xyrem and other products, including Erwinaze, and those other risks detailed from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals'  filings and reports with the Securities and Exchange Commission (Commission File No. 001-33500), including in Jazz Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 and future filings and reports by the company.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

SOURCE Jazz Pharmaceuticals plc

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs